Organogenesis Holdings Inc. Appoints Patrick McGuire as Chief Accounting Officer in Key Leadership Change

Key Highlights

• Appointment of Patrick McGuire, age 40, as Chief Accounting Officer and principal accounting officer effective February 18, 2026
• Departure of David Francisco from the role of principal accounting officer; he will continue as Chief Financial Officer and principal financial officer
• McGuire’s annual base salary set at \$345,000 with no additional changes to his compensation package
• McGuire brings significant experience from prior roles at Cynosure, LLC and PricewaterhouseCoopers LLP
• No related party transactions or family relationships impacting the appointment

Detailed Report

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leader in the pharmaceutical and life sciences sector, announced a significant leadership change on February 18, 2026. The company’s board of directors has appointed Patrick McGuire as the new Chief Accounting Officer (CAO) and principal accounting officer, effective immediately.

About Patrick McGuire

Mr. McGuire, 40, steps into the CAO role after serving as the company’s VP, Corporate Controller since September 2023. His background includes a tenure as Corporate Controller at Cynosure, LLC from July 2022 to September 2023. Before that, he spent more than thirteen years at PricewaterhouseCoopers LLP, focusing on pharmaceutical, life sciences, and medical device organizations, culminating in a Director role from July 2019 to July 2022. McGuire holds a B.A. in Economics and Accounting from the College of the Holy Cross and is a licensed Certified Public Accountant in Massachusetts.

Compensation Details

In connection with his new appointment, Mr. McGuire’s annual base salary has been increased to \$345,000. There are no additional changes to his existing compensation arrangements at this time.

Leadership Transition

The appointment marks the transition of David Francisco out of the principal accounting officer position. Importantly, Mr. Francisco will remain with the company as Chief Financial Officer and will retain his responsibilities as principal financial officer, ensuring continuity in the financial leadership team.

Governance and Compliance

• There are no family relationships between Mr. McGuire and any company director or executive officer.
• There are no arrangements or understandings between Mr. McGuire and any other person pursuant to which he was selected for the role.
• Mr. McGuire is not a party to any transaction with the company requiring disclosure under Item 404(a) of Regulation S-K.

Why Investors Should Care

This leadership change signals Organogenesis Holdings Inc.’s commitment to strengthening its financial controls and leadership team with experienced professionals. Appointing a new principal accounting officer with a deep background in auditing and compliance could enhance investor confidence in the company’s financial reporting and governance. The seamless transition ensures ongoing stability, as CFO David Francisco remains in his strategic role.

The market may react to this appointment, especially given Mr. McGuire’s extensive experience in the sector and the company’s focus on regulatory compliance and financial accuracy. Such governance improvements are often viewed favorably by shareholders and analysts, and could influence the company’s share price, particularly if investors see this as a move to further strengthen the integrity of Organogenesis’s financial operations.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a Delaware-incorporated company specializing in pharmaceutical preparations, with its principal office located at 85 Dan Road, Canton, MA 02021. The company’s Class A Common Stock (\$0.0001 par value) trades on the Nasdaq Capital Market under the ticker symbol ORGO.

Disclaimer: This article is based on public filings and is for informational purposes only. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions. The information provided does not constitute investment advice, and the author assumes no responsibility for actions taken based on this content.

View Organogenesis Holdings Inc. Historical chart here